7 news items
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
CMPS
8 May 24
and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
CMPS
8 May 24
control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied
Compass Pathways to announce first quarter financial results on May 8, 2024
CMPS
3 May 24
. The information that Compass posts on these channels and websites could be deemed to be material information. As a result, Compass encourages investors
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
CMPS
2 May 24
and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
CMPS
29 Apr 24
to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted
mkb2u5u5
CMPS
1 Apr 24
. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media
ztdhp8fmsetn4x8kmkj1sq o3v2
ALLG
BLDP
CC
1 Apr 24
it identified four material weaknesses amid its internal control over financial reporting.
Now Read This: Insiders Buying Outlook Therapeutics And 2 Other Stocks
- Prev
- 1
- Next